Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

1(33.3%)

N/A

1(33.3%)

Phase 4

1(33.3%)

3Total

Phase 3(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT04505774Phase 4Completed

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Role: lead

NCT03861767Phase 3Terminated

REMAP Trial for Optimizing Surgical Outcomes at UPMC

Role: lead

NCT06164691Not ApplicableTerminated

Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer

Role: lead

NCT02651909Completed

Utilization of TEG to Monitor Rivaroxaban Activity

Role: lead

All 4 trials loaded